PMID- 29124076
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220310
IS  - 2325-9671 (Print)
IS  - 2325-9671 (Electronic)
IS  - 2325-9671 (Linking)
VI  - 5
IP  - 10
DP  - 2017 Oct
TI  - Clinical Outcomes of Hip Arthroscopic Surgery in Patients With Femoral 
      Retroversion: A Matched Study to Patients With Normal Femoral Anteversion.
PG  - 2325967117732726
LID - 10.1177/2325967117732726 [doi]
LID - 2325967117732726
AB  - BACKGROUND: Femoral retroversion has been noted as a possible risk factor for 
      poor clinical results after hip arthroscopic surgery. PURPOSE: To compare the 
      outcomes of the arthroscopic treatment of hip abnormalities in patients with 
      femoral retroversion to patients with femoral anteversion between 10 degrees  and 20 degrees . 
      STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: Between November 2011 
      and September 2013, 790 hip arthroscopic procedures were performed at a single 
      institution. Of these, 59 hips (7.5%) were located in patients with femoral 
      version </=0 degrees , calculated using preoperative magnetic resonance imaging. These 
      patients were pair matched, based on body mass index +/-5 kg/m(2), age +/-5 years, 
      and Tonnis grade, with 59 patients with femoral anteversion between 10 degrees  and 20 degrees . 
      Exclusion criteria included Perthes disease, inflammatory arthritis, slipped 
      capital femoral epiphysis, previous hip surgery, abductor repair, lateral 
      center-edge angle <20 degrees , Tonnis grade >1, and acetabular profunda or protrusio. 
      Patient-reported outcomes (PROs) were recorded preoperatively, at 3 months 
      postoperatively, and annually thereafter. The PROs utilized were the modified 
      Harris Hip Score (mHHS), Non-Arthritic Hip Score (NAHS), and Hip Outcome 
      Score-Sports-Specific Subscale (HOS-SSS). The visual analog scale (VAS) was 
      collected to assess the patients' pain; patient satisfaction scores (0-10) were 
      also collected. Radiographs were collected at the above time intervals as well. 
      RESULTS: Two patients from the control group and 1 patient from the retroverted 
      group required total hip arthroplasty at a mean 19.5 and 26.3 months, 
      respectively. Both groups demonstrated significant improvement from their 
      preoperative state in all PRO and VAS scores (P < .001). No differences in 
      preoperative, postoperative, or change in PRO and VAS scores between the groups 
      were noted. CONCLUSION: Patients with femoral retroversion reported similar 
      outcomes compared to patients with normal femoral version when undergoing hip 
      arthroscopic surgery. Both groups had similar improvements from the preoperative 
      state.
FAU - Hartigan, David E
AU  - Hartigan DE
AD  - American Hip Institute, Westmont, Illinois, USA.
AD  - Mayo Clinic, Rochester, Minnesota, USA.
FAU - Perets, Itay
AU  - Perets I
AD  - American Hip Institute, Westmont, Illinois, USA.
FAU - Walsh, John P
AU  - Walsh JP
AD  - American Hip Institute, Westmont, Illinois, USA.
AD  - College of Osteopathic Medicine, Des Moines University, Des Moines, Iowa, USA.
FAU - Chaharbakhshi, Edwin O
AU  - Chaharbakhshi EO
AD  - American Hip Institute, Westmont, Illinois, USA.
AD  - Stritch School of Medicine, Loyola University Chicago, Chicago, Illinois, USA.
FAU - Yuen, Leslie C
AU  - Yuen LC
AD  - American Hip Institute, Westmont, Illinois, USA.
FAU - Domb, Benjamin G
AU  - Domb BG
AD  - American Hip Institute, Westmont, Illinois, USA.
AD  - Hinsdale Orthopaedics, Hinsdale, Illinois, USA.
LA  - eng
PT  - Journal Article
DEP - 20171027
PL  - United States
TA  - Orthop J Sports Med
JT  - Orthopaedic journal of sports medicine
JID - 101620522
PMC - PMC5661671
OTO - NOTNLM
OT  - femoral retroversion
OT  - hip arthroscopic surgery
OT  - hip impingement
OT  - hip retroversion
COIS- One or more of the authors has declared the following conflict of interest or 
      source of funding: B.G.D. is a board member of the American Hip Institute, which 
      receives funding from Arthrex, ATI, Breg, Pacira, and Stryker; is a consultant 
      for Amplitude, Arthrex, Medacta, Pacira, and Stryker; and receives royalties from 
      Arthrex, DJO Global, and Orthomerica.
EDAT- 2017/11/11 06:00
MHDA- 2017/11/11 06:01
PMCR- 2017/10/27
CRDT- 2017/11/11 06:00
PHST- 2017/11/11 06:00 [entrez]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2017/11/11 06:01 [medline]
PHST- 2017/10/27 00:00 [pmc-release]
AID - 10.1177_2325967117732726 [pii]
AID - 10.1177/2325967117732726 [doi]
PST - epublish
SO  - Orthop J Sports Med. 2017 Oct 27;5(10):2325967117732726. doi: 
      10.1177/2325967117732726. eCollection 2017 Oct.